Portfolio Lab

Innoviva, Inc.

  • Stock
  • Ticker INVA
  • ISIN US45781M1018
  • Nasdaq

Health care · Pharmaceuticals · USA

$18.41 0.00%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Innoviva, Inc. since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

INVAGlobal equities (VT)

$10,000 grew to $16,859. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −59.6% in 03/2020, measured from the peak in 01/2019. It took 37 months to get back to the old peak.

1-year return
−13.0%
5-year return p.a.
+1.5%
10-year return p.a.
+5.4%
Volatility p.a.
30.5%
Largest decline
−59.6%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue928910010811598120106
Gross profit7873837676769184
Operating income4341493539385142
Net income20-476490164187-83-74
Earnings per share0.31-0.740.771.081.952.22-1.14-1.03
Balance sheet
Total assets1,3011,2541,3341,4291,6351,8371,7031,538
Liabilities610607619419462495469400
Equity6916477151,0101,1731,3421,2331,138
Cash305319398477551603570581
Long-term debt256257257257258258258259
Cash flow
Operating cash flow5949445055355242
Capital expenditure0.00.00.0-1.10.0-0.5-0.40.0
Free cash flow5949444955355242

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2021 at +39.2%, weakest 2022 at −23.2%. 6 of 9 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
4 Nov 2026−$1.03
5 Aug 2026−$1.14
6 May 2026$2.22
25 Feb 2026$1.95
5 Nov 2025$1.08
6 Aug 2025$0.77
7 May 2025−$0.74
26 Feb 2025$0.31
6 Nov 2024$0.02
31 Jul 2024−$0.55
8 May 2024$0.46
29 Feb 2024$0.75

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€1.2bn
Market cap in trading currency
$1.31bn
Enterprise value
$986m
P/E
9.2
P/S
2.99
P/B
1.15
EV/Sales
2.25
EV/EBITDA
–
Earnings yield
10.9%
FCF yield
13.9%

Results (last four quarters)

Revenue
$438m
Gross profit
$326m
EBITDA
–
Net income
$193m
Earnings per share
$2.00
Revenue per share
$6.17
Revenue growth
−1.6%
Earnings growth
−182.2%

Profitability

Gross margin
74.5%
Operating margin
38.8%
Net margin
44.1%
Return on equity
18.0%
Return on assets
12.6%

Balance sheet and cash flow

Cash
$581m
Cash per share
$8.18
Financial debt
$259m
Debt/equity %
23
Current ratio
15.44
Book value per share
$16.00
Operating cash flow
$183m
Free cash flow
$183m

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
0%
Ex-dividend date
–

Shares and trading

Shares outstanding
71.1m
Volume
1.15m
Avg. volume 3 months
838,995
Relative volume
1.3

Price and technicals

Price
$18.41
1 day
0.0%
52-week high
$24.24
52-week low
$18.30
Distance to 52-week high
−24.1%
Distance to 52-week low
+0.6%
Distance to 50-day line
−9.9%
Distance to 200-day line
−15.6%
RSI (14)
29
Volatility 1M
38.3%

Performance

1 week
−3.3%
1 month
−12.6%
3 months
−12.5%
6 months
−18.0%
YTD
−7.9%
1 year
−13.4%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has INVA performed since 11/2016?

$10,000 grew to $16,859 by 20 Nov 2026, which is +5.4% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is INVA?

Volatility was 30.5% per year, measured on monthly returns. The largest decline from a peak was −59.6%, with the low in 03/2020.

How does INVA compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, INVA returned +5.4% at 30.5%. The correlation of monthly returns was 0.27; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Innoviva, Inc. (INVA): Return and risk | Portfolio Lab